🟢 Xenetic Biosciences is trading 6.68% up today amid volatility around proposed Santersus acquisition

Xenetic Biosciences is trading at $2.96, up 6.68%, rebounding after volatility around the proposed Santersus acquisition.

• It closed at $2.77 on September 18 following sharp volatility around the transaction.
• The all-stock deal, subject to approval, would give existing shareholders approximately 15% of the combined company and Santersus shareholders roughly 85%.
• No new September 21 announcement or separate overnight catalyst was identified; broader risk-on markets may also be supporting the rebound.